ADPT
Adaptive Biotechnologies Corporation
Set alert
- YTD
- +64.04%
- 1 year
- +57.54%
- Open
- 27.36
- Prev close
- 28.17
- Mkt cap
- 4.25B
- Vol
- 4.26M
- Avg vol
- 2.15M
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.17
- High
- 27.97
- Forward P/E
- -147.76
- Beta
- 2.10
- Short ratio
- 4.56
- Inst. own
- 99.06%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 26.35
- 200-d avg
- 19.56
- 1y target
- 30.21
Key statistics
- Market cap
- 4.25B
- Enterprise value
- 4.57B
- Trailing P/E
- 0.00
- Forward P/E
- -147.76
- PEG ratio
- 0.00
- Price / sales
- 13.80
- Price / book
- 29.67
- EPS (TTM)
- -0.41
- Beta
- 2.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -20.73%
- Revenue (TTM)
- 308.08M
- Revenue growth
- 21.50%
- Free cash flow
- 18.98M
- Total cash
- 344.26M
- Total debt
- 410.50M
- Return on equity
- -38.76%
- Shares outstanding
- 159.60M
- Short % of float
- 9.49%
- 50-day average
- 26.35
- 200-day average
- 19.56
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 30.21
- Target (high)
- 35.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.09552.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.09108 | — | — | — |
| Jul 28, 2026 | Jun 30, 2026 | -0.13361 | -0.25 | -0.12 | -87.11% |
| May 5, 2026 | Mar 31, 2026 | -0.16 | -0.13 | +0.03 | +18.75% |
| Feb 5, 2026 | Dec 31, 2025 | -0.19 | -0.09 | +0.10 | +52.63% |
| Nov 6, 2025 | Sep 30, 2025 | -0.18 | 0.06 | +0.24 | +133.33% |
| Aug 5, 2025 | Jun 30, 2025 | -0.24 | -0.17 | +0.07 | +29.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Goldman Sachs | init | — | Buy |
| Sep 22, 2026 | BTIG | main | Buy | Buy |
| Aug 4, 2026 | Piper Sandler | main | Overweight | Overweight |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- adaptivebiotech.com
News
- Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure
- Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock
- Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock
- MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- Alger Small Cap Focus Fund Q3 2026 Portfolio Update
- Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock
- Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
- TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
- Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27
- Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100
Your note
Sign in to keep a note on ADPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENZENO SHARON | Officer | Sale | Jun 28, 2026 | 221,278 |
| BOBULSKY SUSAN | Officer | Sale | Oct 5, 2026 | 389,350 |
| LO FRANCIS | Officer | Sale | Sep 30, 2026 | 223,367 |
| NEUPERT PETER M | Director | Sale | Aug 16, 2026 | 130,625 |
| OWEN KATEY EINTERZ | Director | Stock Gift | Aug 30, 2026 | 66,100 |
| PELLINI MICHAEL J | Director | Stock Award(Grant) | Mar 3, 2025 | 69,690 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Viking Global Investors, L.P. | 18.79% | 29,993,708 | 799.03M | Jun 29, 2026 |
| Blackrock Inc. | 9.49% | 15,139,159 | 403.31M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.01% | 6,403,587 | 170.59M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.70% | 5,911,366 | 157.48M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.43% | 5,476,231 | 145.89M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 2.90% | 4,625,859 | 123.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.03% | 4,834,309 | 128.79M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 4,122,023 | 109.81M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.14% | 1,825,333 | 48.63M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.09% | 1,742,854 | 46.43M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.06% | 1,684,998 | 44.89M | Jul 30, 2026 |
| ALGER FUNDS-Alger Small Cap Focus Fund | 0.94% | 1,494,214 | 39.81M | Jul 30, 2026 |